Skip to content

Woodsmoke Exposure and Cardiovascular Function

Cardiovascular Effects of Experimental Exposure to Woodsmoke in Man

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01488500
Enrollment
20
Registered
2011-12-08
Start date
2011-11-30
Completion date
2012-05-31
Last updated
2012-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Inflammation, Systemic Inflammation

Keywords

Wood smoke, inflammation, lung function, arterial stiffness, heart rate variability, Respiratory and systemic inflammation following exposure to woodsmoke in healthy volunteers

Brief summary

Air pollution is linked to respiratory and cardiovascular disease. Wood smoke is a common air in many parts of the world and previous studies indicate that wood smoke induce oxidative stress in the respiratory tract. It is not determined how different types of biomass combustion affect human health. In this study the investigators plan to investigate how inhalation of wood smoke and pellets smoke affect respiratory and cardiovascular health.

Interventions

OTHERBronchoscopy

24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.

Sponsors

Umeå University
CollaboratorOTHER
University of Edinburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers

Exclusion criteria

* Use of regular medication except the oral contraceptive pill * Current smokers * Significant occupation exposure to air pollution * Intercurrent illness

Design outcomes

Primary

MeasureTime frameDescription
Respiratory inflammation24 hours after exposure to air or woodsmokeBronchoscopy will be performed, and samples collected by bronchoalveolar lavage and bronchial biopsy. Samples will be analysed for cell counts, histology and inflammatory markers.

Secondary

MeasureTime frameDescription
Central arterial stiffnessBaseline and for 1 hour after exposureCentral arterial stiffness will be measured at baseline and for the 1 hour following the exposure using the SphygmoCor and Vicorder devices
Heart rate variability24 hours after the exposureContinuous electrocardiograms will be recorded using a holter monitor to determine heart rate variability
Systemic inflammation24 hours after the exposureBlood samples will be taken at intervals following the exposure to woodsmoke to measure circulating inflammatory markers
Lung functionBaseline and 24hrs after exposureLung function will be assessed using spirometry before and after each exposure

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026